Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05251116 · ClinicalTrials.gov registry record · NA

Study of an Interstitial Fluid Glucose Sensor

A NA study of Diabete Mellitus, sponsored by Abbott Diabetes Care.

Completed
Registry status
NA
Development phase
332
Enrollment target
5
Study locations

NCT05251116 is a NA study of Diabete Mellitus that has completed, run by Abbott Diabetes Care. The registered enrollment target is 332 participants, above the 153-participant average among 6 other Diabete Mellitus trials with a reported enrollment target (117% higher). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05251116, a NA study of Diabete Mellitus, has completed, sponsored by Abbott Diabetes Care.

COMPLETED
Registry status
NA
Development phase
332 participants
Enrollment target
5
Study locations

Study Summary

To characterize the System performance with respect to Yellow Springs Instrument (YSI) reference venous plasma measurements. Safety of the investigational device will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.

Conditions Studied

Interventions

  • DEVICE FreeStyle Libre

Study Locations (5)

California

  • Sansum Diabetes Research Institute - Santa Barbara

Georgia

  • Atlanta Diabetes Associates - Atlanta

Idaho

  • Rocky Mountain Diabetes & Osteoporosis Center - Idaho Falls

Texas

  • Diabetes and Glandular Disease Clinic - San Antonio

Washington

  • Rainier Clinical Research - Renton

Trial Details

FieldValue
Enrollment Target 332 participants
Start Date 2021-12-11
Est. Completion 2022-08-15
Phase NA

Sponsor

Abbott Diabetes Care

26 total trials

What the Registry Record Tells You About NCT05251116

The ClinicalTrials.gov registry entry for NCT05251116 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 153-participant average among 6 other Diabete Mellitus trials with a reported enrollment target (117% higher). The listed sponsor is Abbott Diabetes Care, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabete Mellitus appearing as the primary indexed condition, and to 1 intervention - of which FreeStyle Libre is the first listed.

NCT05251116 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Idaho.

Frequently Asked Questions

What is clinical trial NCT05251116 about?

NCT05251116 is a clinical study titled "Study of an Interstitial Fluid Glucose Sensor". To characterize the System performance with respect to Yellow Springs Instrument (YSI) reference venous plasma measurements. Safety of the investigational device will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.

What is the current status of trial NCT05251116?

This trial is currently completed. It is a NA study. The enrollment target is 332 participants. The study started on 2021-12-11. Estimated completion is 2022-08-15.

What conditions does trial NCT05251116 study?

This clinical trial studies the following conditions: Diabete Mellitus.

What interventions are being tested in trial NCT05251116?

The interventions under investigation include: FreeStyle Libre (DEVICE).

Who is sponsoring clinical trial NCT05251116?

This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05251116 being conducted?

This trial has 5 study locations across California, Georgia, Idaho, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabete Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.